ISL
HAE icon

Ingalls & Snyder LLC’s Haemonetics HAE Stock Holding History

Ingalls & Snyder LLC’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-4,900
Closed -$202K – 371
2015
Q2 		$202K Hold
4,900
– – 0.01% 346
2015
Q1 		$220K Buy
+4,900
New +$205K 0.01% 330

Other funds holding HAE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return
Barrow, Hanley, Mewhinney & Strauss
Barrow, Hanley, Mewhinney & Strauss Dallas, Texas $33B AUM 40.62% 1-Year Est. Return
BCIM
Black Creek Investment Management Toronto, Ontario, Canada $1.78B AUM 5.83% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
WHG
Westwood Holdings Group Dallas, Texas $13.3B AUM 29.38% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Ingalls & Snyder LLC's HAE Position: Q3 2015 in Review

Ingalls & Snyder LLC sold out of Haemonetics (HAE) in Q3 2015, closing a stake of 4,900 shares — an estimated $202K sold.

Ingalls & Snyder LLC first reported a position in HAE in Q1 2015 and held it in 2 quarters. The position peaked at $220K in Q1 2015. 172 funds tracked by Wall St. Rank hold HAE as of Q3 2015.

  • Ingalls & Snyder LLC reported no remaining Haemonetics position as of Q3 2015 after selling out during the quarter.
  • Ingalls & Snyder LLC sold 4,900 Haemonetics shares in Q3 2015, an estimated $202K.
  • Ingalls & Snyder LLC first reported a position in Haemonetics in Q1 2015 and held it in 2 quarters.
  • Ingalls & Snyder LLC's Haemonetics position peaked at $220K in Q1 2015.
  • 172 funds tracked by Wall St. Rank held Haemonetics as of Q3 2015.

Based on Ingalls & Snyder LLC's 13F filing for Q3 2015, filed 27 Oct 2015.